$TYRA
Tyra Biosciences, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023009181 Filed on March 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.926M $4.618M $15.92M
YoY Change -24.34% 72.18% 181.65%
% of Gross Profit
Research & Development $10.41M $10.40M $43.01M
YoY Change 7.91% 43.45% 108.41%
% of Gross Profit
Depreciation & Amortization $83.00K $82.00K $296.0K
YoY Change 29.69% 64.0% 111.43%
% of Gross Profit
Operating Expenses $14.33M $15.02M $58.93M
YoY Change -3.37% 51.21% 124.16%
Operating Profit -$14.33M -$58.93M
YoY Change -3.37% 124.16%
Interest Expense $2.455M $2.156M $3.652M
YoY Change 13538.89% 43020.0% 27992.31%
% of Operating Profit
Other Income/Expense, Net $2.454M -$33.00K $3.602M
YoY Change 30575.0% 1000.0% -60133.33%
Pretax Income -$11.88M -$12.90M -$55.33M
YoY Change -19.87% 29.86% 110.41%
Income Tax $2.000K
% Of Pretax Income
Net Earnings -$11.88M -$12.90M -$55.33M
YoY Change -19.87% 29.86% 110.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28 -$1.32
Diluted Earnings Per Share -$0.28 -$0.31 -$1.32
COMMON SHARES
Basic Shares Outstanding 42.44M 42.20M 41.88M
Diluted Shares Outstanding 42.39M 41.88M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $241.7M $251.2M $251.2M
YoY Change -17.37% -16.87% -16.87%
Cash & Equivalents $241.7M $251.2M $251.2M
Short-Term Investments $0.00
Other Short-Term Assets $5.008M $6.075M $6.075M
YoY Change 228.18% 224.0% 224.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $246.7M $257.3M $257.3M
YoY Change -16.09% -15.38% -15.38%
LONG-TERM ASSETS
Property, Plant & Equipment $1.048M $1.077M $3.543M
YoY Change 3.97% 4.87% 69.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.874M $4.350M $5.350M
YoY Change 970.17% 1294.23% 863.96%
Total Long-Term Assets $8.346M $8.893M $8.893M
YoY Change 68.74% 236.35% 236.35%
TOTAL ASSETS
Total Short-Term Assets $246.7M $257.3M $257.3M
Total Long-Term Assets $8.346M $8.893M $8.893M
Total Assets $255.1M $266.2M $266.2M
YoY Change -14.69% -13.21% -13.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.280M $1.145M $1.145M
YoY Change -5.6% 91.15% 91.15%
Accrued Expenses $2.402M $4.556M $4.556M
YoY Change -32.24% 51.01% 51.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.682M $5.701M $5.701M
YoY Change -24.87% 57.66% 57.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $139.0K $169.0K $2.651M
YoY Change -54.13% -53.95% 96.66%
Total Long-Term Liabilities $139.0K $169.0K $2.651M
YoY Change -54.13% -53.95% 96.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.682M $5.701M $5.701M
Total Long-Term Liabilities $139.0K $169.0K $2.651M
Total Liabilities $6.265M $8.352M $8.352M
YoY Change -19.55% 68.25% 68.25%
SHAREHOLDERS EQUITY
Retained Earnings -$107.6M -$95.70M
YoY Change 94.89% 137.05%
Common Stock $356.4M $353.5M
YoY Change 2.88% 3.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $248.8M $257.8M $257.8M
YoY Change
Total Liabilities & Shareholders Equity $255.1M $266.2M $266.2M
YoY Change -14.69% -13.21% -13.21%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$11.88M -$12.90M -$55.33M
YoY Change -19.87% 29.86% 110.41%
Depreciation, Depletion And Amortization $83.00K $82.00K $296.0K
YoY Change 29.69% 64.0% 111.43%
Cash From Operating Activities -$9.847M -$11.98M -$50.29M
YoY Change 10.33% 32.7% 111.77%
INVESTING ACTIVITIES
Capital Expenditures $41.00K $21.00K $559.0K
YoY Change -82.85% -120.0% -15.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$41.00K -$21.00K -$559.0K
YoY Change -82.85% -80.0% -13.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 376.0K 3.000K 632.0K
YoY Change 57.98% -100.2% -99.8%
NET CHANGE
Cash From Operating Activities -9.847M -11.98M -50.29M
Cash From Investing Activities -41.00K -21.00K -559.0K
Cash From Financing Activities 376.0K 3.000K 632.0K
Net Change In Cash -9.512M -12.00M -50.21M
YoY Change 6.57% 12.75% -117.5%
FREE CASH FLOW
Cash From Operating Activities -$9.847M -$11.98M -$50.29M
Capital Expenditures $41.00K $21.00K $559.0K
Free Cash Flow -$9.888M -$12.00M -$50.84M
YoY Change 7.9% 34.5% 108.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001863127
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40800
CY2022 dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2022 dei City Area Code
CityAreaCode
619
CY2022 dei Local Phone Number
LocalPhoneNumber
728-4760
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
TYRA
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
121800000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42436215
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
San Diego, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251213000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
302182000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6075000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1875000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
257288000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
304057000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
243000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1027000
CY2022Q4 tyra Right Of Use Asset
RightOfUseAsset
2466000
CY2021Q4 tyra Right Of Use Asset
RightOfUseAsset
1062000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4350000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2022Q4 us-gaap Assets
Assets
266181000
CY2021Q4 us-gaap Assets
Assets
306701000
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
47000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1145000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
599000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
140000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
202000
CY2022Q4 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
59000
CY2021Q4 tyra Accrued And Other Related Parties
AccruedAndOtherRelatedParties
0
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2815000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5701000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3616000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2482000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
981000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
169000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
367000
CY2022Q4 us-gaap Liabilities
Liabilities
8352000
CY2021Q4 us-gaap Liabilities
Liabilities
4964000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42634459
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42536183
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42353550
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41441135
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
353521000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
342104000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95696000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40371000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
266181000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306701000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43008000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20636000
CY2022 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
765000
CY2021 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
435000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15919000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5652000
CY2022 us-gaap Operating Expenses
OperatingExpenses
58927000
CY2021 us-gaap Operating Expenses
OperatingExpenses
26288000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-58927000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-26288000
CY2022 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
3652000
CY2021 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
13000
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
50000
CY2021 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
19000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3602000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26294000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41883904
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41883904
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13780546
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13780546
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-13638000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
157274000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
181220000
CY2021 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
89000
CY2021 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
199000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2887000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26294000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
632000
CY2022 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
197000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10588000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26294000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
296000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
140000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
10588000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2887000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
8238000
CY2021 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2108000
CY2022Q4 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
12000
CY2021Q4 tyra Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions
AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions
47000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2357000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1492000
CY2022 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
34000
CY2021 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
135000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50285000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23745000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
559000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
661000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
16000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-559000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-645000
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
181220000
CY2022 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
632000
CY2021 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
514000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
632000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
311348000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50212000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
286958000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15467000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251213000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
302182000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
243000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1572000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1238000
CY2022 tyra Conversion Of Convertible Preferred Stock In Connection With Initial Public Offering
ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering
0
CY2021 tyra Conversion Of Convertible Preferred Stock In Connection With Initial Public Offering
ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering
157274000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
209000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95700000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251200000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accounting estimates and management judgments reflected in the financial statements include: normal recurring accruals, including the accrual of research and development expenses and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.</span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1000000.0
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000
CY2022 us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero.
CY2022 tyra Dividend Yield
DividendYield
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1538000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1196000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
461000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
169000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1077000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1027000
CY2022 us-gaap Depreciation
Depreciation
296000
CY2021 us-gaap Depreciation
Depreciation
140000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2854000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1278000
CY2022Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1028000
CY2021Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1257000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
61000
CY2022Q4 tyra Accrued Other General And Administrative Fee
AccruedOtherGeneralAndAdministrativeFee
440000
CY2021Q4 tyra Accrued Other General And Administrative Fee
AccruedOtherGeneralAndAdministrativeFee
219000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4416000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2815000
CY2022Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
5890869
CY2021Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
3771516
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10989684
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8535790
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3771516
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.18
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28901000
CY2022 tyra Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod
2685077
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.71
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
52357
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.90
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
513367
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.84
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5890869
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.91
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13492000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1623928
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.80
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6211000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5890869
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.91
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
13492000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10588000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2887000
CY2022 tyra Forfeitures Resulted In The Reversal Of Compensation Expense
ForfeituresResultedInTheReversalOfCompensationExpense
1200000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
23300000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2022 tyra Incremental Stock Based Compensation Recorded Due To Terminations
IncrementalStockBasedCompensationRecordedDueToTerminations
2000000.0
CY2022 tyra Accelerate Expense Or Compensation Cost Expense Recognized Due To Termination
AccelerateExpenseOrCompensationCostExpenseRecognizedDueToTermination
1200000
CY2022 tyra Stock Compensation Expense Related To Modification Of Options
StockCompensationExpenseRelatedToModificationOfOptions
800000
CY2022Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
277081
CY2021Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
599878
CY2022Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
200000
CY2021Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
400000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-55325000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26294000
CY2022 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42627825
CY2021 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
15206879
CY2022 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-269174
CY2021 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-732418
CY2022 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
474746
CY2021 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
693915
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41883904
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41883904
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13780546
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13780546
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6171778
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4866564
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11618000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5392000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-58000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1661000
CY2022 tyra Incometaxreconciliation Officers Compensation
IncometaxreconciliationOfficersCompensation
598000
CY2021 tyra Incometaxreconciliation Officers Compensation
IncometaxreconciliationOfficersCompensation
28000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
707000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
86000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2093000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
680000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12466000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7620000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11596000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9297000
CY2022Q4 tyra Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
7097000
CY2021Q4 tyra Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
0
CY2022Q4 tyra Deferred Tax Assets Tax Credits
DeferredTaxAssetsTaxCredits
2958000
CY2021Q4 tyra Deferred Tax Assets Tax Credits
DeferredTaxAssetsTaxCredits
874000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1016000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
239000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1090000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
470000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23757000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10880000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23085000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10618000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
672000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
262000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
151000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
37000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
521000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
225000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
672000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
262000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23100000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12500000
CY2022 tyra Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage
NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage
0.80
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1142000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
91000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
366000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
312000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
66000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
739000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1574000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1142000
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
322000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
331000
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
0
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
81000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
73000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
56000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
16000
CY2022 us-gaap Lease Cost
LeaseCost
459000
CY2021 us-gaap Lease Cost
LeaseCost
420000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
300000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
309000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
318000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
328000
CY2022Q4 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2381000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3636000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1014000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2622000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
140000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2482000
CY2022Q4 tyra Minimum Lease Payments For Leases Not Yet Commenced
MinimumLeasePaymentsForLeasesNotYetCommenced
5500000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2022 dei Auditor Firm
AuditorFirmId
42

Files In Submission

Name View Source Status
0000950170-23-009181-index-headers.html Edgar Link pending
0000950170-23-009181-index.html Edgar Link pending
0000950170-23-009181.txt Edgar Link pending
0000950170-23-009181-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img22602870_0.jpg Edgar Link pending
img22602870_1.jpg Edgar Link pending
img22602870_10.jpg Edgar Link pending
img22602870_11.jpg Edgar Link pending
img22602870_12.jpg Edgar Link pending
img22602870_13.jpg Edgar Link pending
img22602870_14.jpg Edgar Link pending
img22602870_15.jpg Edgar Link pending
img22602870_16.jpg Edgar Link pending
img22602870_17.jpg Edgar Link pending
img22602870_18.jpg Edgar Link pending
img22602870_19.jpg Edgar Link pending
img22602870_2.jpg Edgar Link pending
img22602870_20.jpg Edgar Link pending
img22602870_21.jpg Edgar Link pending
img22602870_22.jpg Edgar Link pending
img22602870_23.jpg Edgar Link pending
img22602870_24.jpg Edgar Link pending
img22602870_25.jpg Edgar Link pending
img22602870_26.jpg Edgar Link pending
img22602870_27.jpg Edgar Link pending
img22602870_28.jpg Edgar Link pending
img22602870_29.jpg Edgar Link pending
img22602870_3.jpg Edgar Link pending
img22602870_30.jpg Edgar Link pending
img22602870_31.jpg Edgar Link pending
img22602870_4.jpg Edgar Link pending
img22602870_5.jpg Edgar Link pending
img22602870_6.jpg Edgar Link pending
img22602870_7.jpg Edgar Link pending
img22602870_8.jpg Edgar Link pending
img22602870_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20221231.htm Edgar Link pending
tyra-20221231.xsd Edgar Link pending
tyra-ex10_14.htm Edgar Link pending
tyra-ex10_16.htm Edgar Link pending
tyra-ex10_19.htm Edgar Link pending
tyra-ex10_21.htm Edgar Link pending
tyra-ex10_22.htm Edgar Link pending
tyra-ex10_5.htm Edgar Link pending
tyra-ex23_1.htm Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending
tyra-ex3_1.htm Edgar Link pending
tyra-20221231_cal.xml Edgar Link unprocessable
tyra-20221231_lab.xml Edgar Link unprocessable
tyra-20221231_def.xml Edgar Link unprocessable
tyra-20221231_pre.xml Edgar Link unprocessable
tyra-20221231_htm.xml Edgar Link completed